AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Abundant Produce

0.027

0.000

Volume:- -

Turnover:150.33K

Market Cap:2.29M

PE:- -

High:0.027

Open:0.027

Low:0.027

Close:0.027

52wk High:0.027

52wk Low:0.027

Shares:84.85M

Float Shares:39.30M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Abbott Laboratories (ABT) Stock After 33% One-Year Slide Is The Market Overreacting

Simply Wall St.

Abbott Laboratories (ABT) Stock Could Be 24% Below Fair Value Before Earnings

Simply Wall St.

Abbott Laboratories (ABT) Is Up 6.4% After European Approval of Dual Glucose‑Ketone Sensors

Simply Wall St.

Insulet Rolls Out Omnipod 5 With Enhanced Algorithm, Abbott Libre 3 Plus Compatibility

MT Newswires Live

Is Abbott Laboratories (ABT) Now Attractive After A 33% One Year Share Price Slide

Simply Wall St.

Assessing Abbott Laboratories (ABT) Valuation After Nutrition Setbacks Legal Uncertainty And Softer Analyst Sentiment

Simply Wall St.

Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT)

Simply Wall St.

Abbott Laboratories Pick of the Week at Smart Insider Following CFO Stock Purchase

MT Newswires Live

Assessing Abbott (ABT) Valuation After New Cardiac Trial Results And Recent Share Price Pullback

Simply Wall St.

Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness

Simply Wall St.

Abbott Laboratories' End-Markets Remain Healthy Despite Mixed Q1 Performance, RBC Says

MT Newswires Live

GUIDANCE: (ABT) Abbott Laboratories Expects 2026 Adjusted EPS Range $5.38 to $5.58, vs. FactSet Est of $5.16

MT Newswires Live

Sector Update: Health Care Stocks Lower Friday Afternoon

MT Newswires Live

Abbott Laboratories Closes Acquisition of Exact Sciences

MT Newswires Live

Abbott Laboratories' Structural Heart Business Could See Upside From Watchman Trial Results, UBS Says

MT Newswires Live

Is It Time To Revisit Abbott Laboratories (ABT) After Recent Share Price Weakness?

Simply Wall St.

A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Moves

Simply Wall St.

Abbott Laboratories Says Late-Breaking Data Supports Safety, Efficacy of Ablation Catheters

MT Newswires Live

Abbott Laboratories' MedTech Business Sustains Momentum Amid Nutrition Weakness, UBS Says

MT Newswires Live

Abbott Laboratories Expects H2 Growth Driven by Product Launches, Nutrition Recovery, RBC Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ABT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ABT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ABT.AU\",,,,,undefined,":{"symbol":"ABT.AU","market":"AU","secType":"STK","nameCN":"Abundant Produce","latestPrice":0.027,"timestamp":1782261244175,"preClose":0.027,"halted":3,"volume":0,"delay":0,"changeRate":0,"nameEN":"Abundant Produce","floatShares":39299635,"shares":84848333,"eps":0,"marketStatus":"Halted","change":0,"latestTime":"06-24 10:34:04 AEST","open":0.027,"high":0.027,"low":0.027,"amount":150332.332916766,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1782280800000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.027,"openAndCloseTimeList":[[1782259200000,1782280800000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ABT.AU\",,,,,undefined,":{"symbol":"ABT.AU","floatShares":39299635,"roa":"--","roe":"--","lyrEps":0,"shares":84848333,"dividePrice":0,"high":0.027,"amplitude":0,"preClose":0.027,"low":0.027,"week52Low":0.027,"pbRate":"--","week52High":0.027,"institutionHeld":0,"latestPrice":0.027,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0.027},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ABT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ABT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ABT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645833449","title":"Abbott Laboratories (ABT) Stock After 33% One-Year Slide Is The Market Overreacting","url":"https://stock-news.laohu8.com/highlight/detail?id=2645833449","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645833449?lang=en_us&edition=fundamental","pubTime":"2026-06-23 18:32","pubTimestamp":1782210777,"startTime":"0","endTime":"0","summary":"If you are wondering whether Abbott Laboratories is attractively priced or just a value trap, the stock’s recent performance and current valuation metrics provide some clear signals to consider.\nThe share price recently closed at US$87.83, with returns roughly flat over the last 30 days, up 0.5%, but down 29.3% year to date and down 32.7% over the past year.\nRecent coverage of Abbott Laboratories has focused on how the stock’s weaker one year and multi year returns, down 32.7% over one year...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-abt-stock-after-33-one-year-slide-is-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-abt-stock-after-33-one-year-slide-is-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4533","LU0058720904.USD","LU2468319806.SGD","LU0868494617.USD","IE00BJJMRZ35.SGD","SGXZ23171101.USD","LU0882574055.USD","LU1057294990.SGD","DCF","IE00BJT1NW94.SGD","BK4211","LU2089984988.USD","LU2133065610.SGD","BK4082","BK4592","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU2211815571.USD","BK4566","LU0170899867.USD","LU0114720955.EUR","LU2237957811.SGD","LU0234572021.USD","ABT","LU1023059063.AUD","BK4588","LU1691799644.USD","LU0266013472.USD","BK4504","LU1721429402.USD","LU1989763427.SGD","LU2237957902.USD","LU0289739699.SGD","LU1989763690.USD","SG9999004303.SGD","IE0002141913.USD","LU1061106388.HKD","LU1721429741.USD","SG9999002224.SGD","LU1914381329.SGD","BK4568","IE00B4R5TH58.HKD","BK4581","LU0122379950.USD","FCF","IE0009355771.USD","LU2324357040.USD","SG9999002232.USD","ABT.AU","LU2112291526.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645943080","title":"Abbott Laboratories (ABT) Stock Could Be 24% Below Fair Value Before Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2645943080","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645943080?lang=en_us&edition=fundamental","pubTime":"2026-06-21 10:27","pubTimestamp":1782008845,"startTime":"0","endTime":"0","summary":"Dividend affirmation and earnings catalyst put Abbott Laboratories stock in focus\nRecent commentary on Abbott Laboratories (ABT) has centered on upcoming earnings and Citi highlighting the value of its diversified healthcare businesses, setting the stage for closer attention to the stock.\nThe reaffirmed quarterly dividend and the approaching July 16 earnings report give investors timely reference points as they weigh Abbott Laboratories stock, its current business mix, and expectations around...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-abt-stock-could-be-24-below-fair-value-b","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-abt-stock-could-be-24-below-fair-value-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABT","ABT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641769271","title":"Abbott Laboratories (ABT) Is Up 6.4% After European Approval of Dual Glucose‑Ketone Sensors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641769271","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641769271?lang=en_us&edition=fundamental","pubTime":"2026-06-07 21:30","pubTimestamp":1780839029,"startTime":"0","endTime":"0","summary":"In late May and early June 2026, Abbott highlighted new data showing rising, often-missed diabetic ketoacidosis cases and secured CE Mark approval in Europe for Libre Duo and Libre Duo 10 Day, its first-of-its-kind dual glucose‑ketone continuous monitoring systems, while awaiting U.S. FDA clearance.\nThe combination of alarming national trends in DKA-related hospitalizations and Abbott’s dual-analyte sensor positions the company to address a critical gap in diabetes care.\nWe’ll now examine...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-abt-is-up-64-after-european-approval-of","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-abt-is-up-64-after-european-approval-of","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4581","IE00BJJMRZ35.SGD","LU2089984988.USD","BK4588","LU1061106388.HKD","IE00B4R5TH58.HKD","IE0009355771.USD","LU1721429402.USD","BK4566","LU2112291526.USD","LU2211815571.USD","SGXZ23171101.USD","LU2237957902.USD","LU0266013472.USD","SG9999002224.SGD","LU1989763427.SGD","LU0289739699.SGD","LU2468319806.SGD","EPV","IE0002141913.USD","LU1989763690.USD","LU0114720955.EUR","LU1057294990.SGD","LU2133065610.SGD","BK4082","IE00BJT1NW94.SGD","LU1914381329.SGD","LU0170899867.USD","IE00BFTCPJ56.SGD","SG9999004303.SGD","SGXZ41872573.SGD","LU0868494617.USD","BK4585","LU1721429741.USD","LU2324357040.USD","ABT.AU","BK4504","SG9999002232.USD","IE00B2B36J28.USD","BK4592","ABT","LU1691799644.USD","BK4568","LU0058720904.USD","LU1023059063.AUD","LU0234572021.USD","LU0122379950.USD","LU2237957811.SGD","LU0882574055.USD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640290460","title":"Insulet Rolls Out Omnipod 5 With Enhanced Algorithm, Abbott Libre 3 Plus Compatibility","url":"https://stock-news.laohu8.com/highlight/detail?id=2640290460","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640290460?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:35","pubTimestamp":1780490144,"startTime":"0","endTime":"0","summary":"Insulet  said Wednesday that it has begun rolling out algorithm enhancements for its Omnipod 5 Automated Insulin Delivery system following clearance from the US Food and Drug Administration.The company said Omnipod 5 is now compatible with Abbott's  Libre 3 Plus sensor in the US, providing users with additional continuous glucose monitoring options and allowing caregiver monitoring through the LibreLinkUp app.The update introduces a new 100 mg/dL Target Glucose setting and helps keep users in Automated Mode with fewer interruptions even during prolonged high-glucose events, the company said.The enhancements will be delivered via over-the-air software updates as compatible Pods become available through US retail channels, Insulet added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0266013472.USD","IE00BJJMRZ35.SGD","ABT","LU0170899867.USD","BK4566","LU1057294990.SGD","LU2112291526.USD","SGXZ23171101.USD","IE00BJT1NW94.SGD","BK4588","BK4592","BK4568","BK4551","LU0882574055.USD","LU2133065610.SGD","LU0058720904.USD","LU2237957902.USD","LU0234572021.USD","BK4082","IE00BFTCPJ56.SGD","LU1989763690.USD","LU1721429741.USD","LU0868494617.USD","LU2065170008.USD","LU0122379950.USD","IE00B2B36J28.USD","LU2211815571.USD","LU2065171402.SGD","IE0009355771.USD","PODD","SGXZ41872573.SGD","LU1261432733.SGD","SG9999002224.SGD","BK4533","LU1691799644.USD","SG9999004303.SGD","LU2065171311.SGD","LU2237957811.SGD","LU0728928796.USD","LU1084165304.USD","BK4585","BK4504","LU1061106388.HKD","IE00B4R5TH58.HKD","IE0002141913.USD","LU1914381329.SGD","LU1119994496.HKD","ABT.AU","LU2468319806.SGD","LU1721429402.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640947420","title":"Is Abbott Laboratories (ABT) Now Attractive After A 33% One Year Share Price Slide","url":"https://stock-news.laohu8.com/highlight/detail?id=2640947420","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640947420?lang=en_us&edition=fundamental","pubTime":"2026-06-03 01:22","pubTimestamp":1780420934,"startTime":"0","endTime":"0","summary":"Wondering whether Abbott Laboratories at US$87.78 is starting to look interesting on valuation, or if the market still sees more downside risk than upside.\nThe stock is up 0.4% over the last week but down 1.9% over the last 30 days, with year to date and 1 year returns declining 29.3% and 32.9% respectively, which puts recent moves in sharp contrast to longer term performance.\nThese returns have kept Abbott Laboratories in focus alongside ongoing sector wide interest in healthcare companies,...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-now-attractive-after-a-33-one-yea","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-now-attractive-after-a-33-one-yea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","LU0122379950.USD","LU2089984988.USD","LU0289739699.SGD","BK4568","LU0266013472.USD","ABT.AU","LU1914381329.SGD","IE00BJJMRZ35.SGD","LU1989763427.SGD","BK4581","LU2112291526.USD","LU2468319806.SGD","SGXZ23171101.USD","IE0009355771.USD","LU0868494617.USD","LU0114720955.EUR","IE0002141913.USD","LU1989763690.USD","DCF","LU1691799644.USD","LU0170899867.USD","LU1057294990.SGD","LU2211815571.USD","BK4592","SG9999004303.SGD","LU1721429741.USD","BK4504","LU2237957811.SGD","LU2324357040.USD","SG9999002232.USD","LU0882574055.USD","ABT","BK4566","LU1061106388.HKD","BK4082","IE00BFTCPJ56.SGD","LU2133065610.SGD","IE00B2B36J28.USD","SG9999002224.SGD","SGXZ41872573.SGD","IE00BJT1NW94.SGD","LU0234572021.USD","LU2237957902.USD","BK4533","IE00B4R5TH58.HKD","LU1023059063.AUD","BK4588","LU0058720904.USD","LU1721429402.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635761066","title":"Assessing Abbott Laboratories (ABT) Valuation After Nutrition Setbacks Legal Uncertainty And Softer Analyst Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2635761066","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635761066?lang=en_us&edition=fundamental","pubTime":"2026-05-16 23:38","pubTimestamp":1778945881,"startTime":"0","endTime":"0","summary":"Abbott Laboratories (ABT) is drawing fresh scrutiny after sales declines in its Nutrition business, new product launches and pricing moves, and early signs of recovering volumes, all while analysts grow more cautious on the stock.\nSee our latest analysis for Abbott Laboratories.\nThe share price has come under pressure despite the Exact Sciences acquisition and commentary around legal risks. The stock is down 16.83% on a 1 month share price return, and the 1 year total shareholder return has...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-laboratories-abt-valuation-after-nutrition","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-laboratories-abt-valuation-after-nutrition","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0868494617.USD","SG9999002232.USD","BK4566","ABT","LU0289739699.SGD","SGXZ23171101.USD","LU0058720904.USD","BK4592","BK4533","BK4568","LU0122379950.USD","LU1691799644.USD","SG9999002224.SGD","BK4504","IE00B2B36J28.USD","LU2133065610.SGD","BK4581","BK4588","BK4585","IE00B4R5TH58.HKD","LU0234572021.USD","LU2468319806.SGD","LU2112291526.USD","LU1023059063.AUD","LU2237957902.USD","LU0882574055.USD","LU1989763690.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0114720955.EUR","SG9999004303.SGD","ABT.AU","LU1721429741.USD","LU1721429402.USD","LU1061106388.HKD","BK4082","IE0002141913.USD","LU0170899867.USD","SGXZ41872573.SGD","IE0009355771.USD","LU1914381329.SGD","IE00BFTCPJ56.SGD","LU2324357040.USD","LU2211815571.USD","LU2089984988.USD","LU1989763427.SGD","LU1057294990.SGD","LU0266013472.USD","LU2237957811.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635062227","title":"Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635062227","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635062227?lang=en_us&edition=fundamental","pubTime":"2026-05-15 13:48","pubTimestamp":1778824090,"startTime":"0","endTime":"0","summary":"In recent months, Abbott Laboratories reported Q1 2026 results that modestly exceeded sales and earnings expectations, closed its approximately US$21.00 billion acquisition of Exact Sciences to expand in cancer diagnostics, and continued to contend with extensive infant formula-related litigation and a securities class action. \nAt the same time, the company’s decade-high dividend yield, long record of consecutive quarterly payouts, and growing medical devices footprint contrast with...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/exact-sciences-deal-and-legal-pressures-might-change-the-cas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/exact-sciences-deal-and-legal-pressures-might-change-the-cas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BJJMRZ35.SGD","ABT","LU0170899867.USD","BK4566","LU1057294990.SGD","LU2112291526.USD","SG9999002232.USD","BK4139","LU0114720955.EUR","IE00BJT1NW94.SGD","BK4588","BK4592","BK4568","LU2089984988.USD","LU0882574055.USD","LU1861559042.SGD","LU2133065610.SGD","LU0058720904.USD","LU2237957902.USD","LU0234572021.USD","BK4082","LU1861558580.USD","IE00BFTCPJ56.SGD","LU1989763690.USD","EXAS","LU0289739699.SGD","LU0868494617.USD","LU1721429741.USD","LU0122379950.USD","IE00B2B36J28.USD","LU2211815571.USD","BK4548","BK4581","IE0009355771.USD","SGXZ41872573.SGD","SG9999004303.SGD","SG9999002224.SGD","BK4533","LU1023059063.AUD","LU1691799644.USD","BK4585","BK4504","LU1061106388.HKD","LU1989763427.SGD","IE00B4R5TH58.HKD","LU1914381329.SGD","LU2324357040.USD","ABT.AU","SGXZ23171101.USD","LU1721429402.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633925945","title":"Abbott Laboratories Pick of the Week at Smart Insider Following CFO Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2633925945","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633925945?lang=en_us&edition=fundamental","pubTime":"2026-05-05 21:19","pubTimestamp":1777987149,"startTime":"0","endTime":"0","summary":"Abbott Laboratories  was Smart Insider's stock pick of the week after Chief Financial Officer Philip Boudreau bought $1.1 million worth of company shares at $91.93 apiece on April 23.The CFO owned $6.5 million in stock and more than 200,000 options before the recent transaction, making it \"unlikely\" that he was under \"pressure\" to make \"such a large purchase,\" Smart Insider said in a Tuesday note.Smart Insider renewed the stock +1, or strong positive signal, on April 28.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","LU0882574055.USD","LU2324357040.USD","IE0002141913.USD","IE00BJT1NW94.SGD","BK4581","SG9999002232.USD","IE00BFTCPJ56.SGD","LU0170899867.USD","LU1691799644.USD","LU0234572021.USD","LU0122379950.USD","BK4592","SGXZ23171101.USD","LU1721429741.USD","LU1914381329.SGD","LU2089984988.USD","LU1721429402.USD","LU2211815571.USD","LU2237957811.SGD","LU2237957902.USD","SG9999002224.SGD","IE00BJJMRZ35.SGD","LU0266013472.USD","LU1989763690.USD","IE0009355771.USD","IE00B4R5TH58.HKD","BK4568","LU1989763427.SGD","LU2112291526.USD","SGXZ41872573.SGD","LU1023059063.AUD","BK4588","LU0868494617.USD","LU1057294990.SGD","LU2468319806.SGD","LU2133065610.SGD","BK4566","ABT","LU0114720955.EUR","BK4504","LU0058720904.USD","LU1061106388.HKD","ABT.AU","LU0289739699.SGD","IE00B2B36J28.USD","BK4533","SG9999004303.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630133550","title":"Assessing Abbott (ABT) Valuation After New Cardiac Trial Results And Recent Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2630133550","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630133550?lang=en_us&edition=fundamental","pubTime":"2026-04-27 01:07","pubTimestamp":1777223276,"startTime":"0","endTime":"0","summary":"Fresh late breaking clinical data on Abbott Laboratories (ABT) pulsed field ablation and conduction system pacing platforms, including FlexPulse IDE and ASCEND CSP IDE, has put the company’s cardiac device capabilities firmly in focus for investors.\nSee our latest analysis for Abbott Laboratories.\nDespite the strong cardiology data, Abbott’s recent news flow also includes a large ESOP related shelf registration and mixed first quarter results, alongside a downgrade from Daiwa. The share price...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-abt-valuation-after-new-cardiac-trial-resul","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-abt-valuation-after-new-cardiac-trial-resul","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2237957811.SGD","LU1023059063.AUD","ABT","LU2089984988.USD","LU1061106388.HKD","SGXZ23171101.USD","LU0868494617.USD","LU1691799644.USD","LU0058720904.USD","LU2468319806.SGD","LU1914381329.SGD","LU2237957902.USD","BK4082","LU0266013472.USD","SG9999004303.SGD","BK4592","BK4581","LU1721429741.USD","LU1989763427.SGD","LU0882574055.USD","LU0170899867.USD","SG9999002232.USD","BK4504","IE0009355771.USD","BK4533","LU1057294990.SGD","LU1989763690.USD","LU2112291526.USD","IE00B4R5TH58.HKD","LU2324357040.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0114720955.EUR","SGXZ41872573.SGD","BK4588","BK4568","LU0122379950.USD","ABT.AU","LU1721429402.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","SG9999002224.SGD","BK4566","LU0234572021.USD","LU2211815571.USD","LU2133065610.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628675227","title":"Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2628675227","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628675227?lang=en_us&edition=fundamental","pubTime":"2026-04-19 22:04","pubTimestamp":1776607493,"startTime":"0","endTime":"0","summary":"Why Abbott Laboratories (ABT) is on investors’ radar\nAbbott Laboratories (ABT) is drawing attention after a period of weaker share performance, with the stock showing negative returns over the past year and past 3 months despite sizeable global healthcare operations.\nSee our latest analysis for Abbott Laboratories.\nAt a share price of $96.81, Abbott’s recent trading has been weak, with a 30 day share price return of 8.2% and a 1 year total shareholder return decline of 24.58%, pointing to...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-laboratories-abt-valuation-after-recent-sha-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-laboratories-abt-valuation-after-recent-sha-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4568","LU1023059063.AUD","SGXZ23171101.USD","LU1061106388.HKD","LU0289739699.SGD","LU1914381329.SGD","LU1721429402.USD","LU1989763427.SGD","SGXZ41872573.SGD","BK4533","BK4581","LU2237957902.USD","LU0114720955.EUR","LU0234572021.USD","BK4566","ABT.AU","LU1721429741.USD","LU2237957811.SGD","LU0882574055.USD","SG9999002224.SGD","LU0266013472.USD","BK4588","LU2324357040.USD","LU2112291526.USD","LU2133065610.SGD","SG9999002232.USD","IE00BFTCPJ56.SGD","BK4082","BK4592","LU0058720904.USD","LU0170899867.USD","IE0009355771.USD","LU1691799644.USD","BK4585","LU1989763690.USD","LU2211815571.USD","LU0122379950.USD","IE00BJJMRZ35.SGD","BK4504","IE00BJT1NW94.SGD","ABT","LU1057294990.SGD","IE0002141913.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0868494617.USD","LU2468319806.SGD","SG9999004303.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628207285","title":"Abbott Laboratories' End-Markets Remain Healthy Despite Mixed Q1 Performance, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2628207285","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628207285?lang=en_us&edition=fundamental","pubTime":"2026-04-17 22:47","pubTimestamp":1776437225,"startTime":"0","endTime":"0","summary":"Abbott Laboratories'  end-markets remain healthy despite a lower 2026 organic revenue guidance amid fiscal Q1 challenges and mixed performance, RBC Capital Markets said in a Thursday research note.The company faced Q1 headwinds, including a weaker respiratory season, underperformance in the continuous glucose monitoring segment, challenging US structural heart business trends, and roadblocks in the nutrition sector, analysts wrote.The brokerage said it expects 2026 EPS of $5.48 on revenue of $50.54 billion.The company has visibility to accelerate growth in H2, driven by emerging signs of nutrition business recovery, electrophysiology unit growth, improvements in the core lab diagnostics unit, robust performance in established pharmaceuticals, and the integration of Exact Sciences in the cancer diagnostics business, according to the note.The brokerage reiterated its outperform rating on the stock and adjusted its price target to $130 from $135.Price: 96.67, Change: +1.20, Percent Change","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","LU0882574055.USD","LU2324357040.USD","IE0002141913.USD","IE00BJT1NW94.SGD","BK4581","SG9999002232.USD","IE00BFTCPJ56.SGD","LU0170899867.USD","LU1691799644.USD","LU0234572021.USD","LU0122379950.USD","BK4592","SGXZ23171101.USD","LU1721429741.USD","LU1914381329.SGD","LU2089984988.USD","LU1721429402.USD","LU2211815571.USD","LU2237957811.SGD","LU2237957902.USD","SG9999002224.SGD","IE00BJJMRZ35.SGD","LU0266013472.USD","LU1989763690.USD","IE0009355771.USD","IE00B4R5TH58.HKD","BK4568","LU1989763427.SGD","LU2112291526.USD","SGXZ41872573.SGD","LU1023059063.AUD","BK4588","LU0868494617.USD","LU1057294990.SGD","LU2468319806.SGD","LU2133065610.SGD","BK4566","ABT","LU0114720955.EUR","BK4504","LU0058720904.USD","LU1061106388.HKD","ABT.AU","LU0289739699.SGD","IE00B2B36J28.USD","BK4533","SG9999004303.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627973272","title":"GUIDANCE: (ABT) Abbott Laboratories Expects 2026 Adjusted EPS Range $5.38 to $5.58, vs. FactSet Est of $5.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2627973272","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627973272?lang=en_us&edition=fundamental","pubTime":"2026-04-16 19:33","pubTimestamp":1776339192,"startTime":"0","endTime":"0","summary":"GUIDANCE: (ABT) Abbott Laboratories Expects 2026 Adjusted EPS Range $5.38 to $5.58, vs. FactSet Est of $5.16","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABT","ABT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626112379","title":"Sector Update: Health Care Stocks Lower Friday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2626112379","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626112379?lang=en_us&edition=fundamental","pubTime":"2026-04-11 01:54","pubTimestamp":1775843654,"startTime":"0","endTime":"0","summary":"Health care stocks declined Friday afternoon, with the NYSE Health Care Index decreasing 0.7% and the State Street Health Care Select Sector SPDR ETF  falling 1.2%.The iShares Biotechnology ETF  dropped 1.8%.In corporate news, Replimune  shares tumbled 19%. The company's biologics license application for vusolimogene oderparepvec to treat unresectable advanced cutaneous melanoma was rejected by the US Food and Drug Administration, the regulator said in a complete response letter.Abbott Laboratories  has been ordered by a jury in Chicago to pay $53 million in compensatory damages to a group of families related to four cases over its infant formula, the Chicago Tribune reported. The families accused the company of allegedly failing to inform them that its infant formula could develop a dangerous intestinal disease in premature infants, the report said. Abbott shares fell 2.9%.Organon  is closing in on a deal to be acquired by Sun Pharmaceutical Industries for $12 billion, The Economic Ti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2324357040.USD","LU0266013472.USD","REPL","BK4504","LU0058720904.USD","LU1914381329.SGD","LU2089984988.USD","SG9999002232.USD","XLV","BK4588","IE00BJJMRZ35.SGD","SGXZ23171101.USD","LU2065170008.USD","LU1061106388.HKD","BK4533","LU1989763690.USD","LABU","ABT","ABT.AU","XBI","BK4566","LU0122379950.USD","LU1023059063.AUD","LU2237957902.USD","LU2065171311.SGD","LU0114720955.EUR","LU1721429741.USD","IE00BFTCPJ56.SGD","BK4568","IE0009355771.USD","LU0882574055.USD","BK4139","LU0289739699.SGD","BK4592","LU2237957811.SGD","LU2065169927.USD","IBB","LU1691799644.USD","LU1989763427.SGD","OGN","IE00BJT1NW94.SGD","LU2112291526.USD","LU2468319806.SGD","BK4007","BK4559","IE00B2B36J28.USD","BK4585","LU1721429402.USD","BK4581","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621370957","title":"Abbott Laboratories Closes Acquisition of Exact Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2621370957","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621370957?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:25","pubTimestamp":1774272343,"startTime":"0","endTime":"0","summary":"Abbott Laboratories  said Monday it has completed its acquisition of Exact Sciences , making the company its wholly owned subsidiary.Exact Sciences shares ceased trading on Nasdaq following the transaction completion, the company said.Abbott shares were 1.6% higher in Monday premarket trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0009355771.USD","BK4533","LU2089984988.USD","SG9999002232.USD","BK4566","LU0234572021.USD","BK4581","IE00B4R5TH58.HKD","LU1691799644.USD","IE00BJT1NW94.SGD","SG9999002224.SGD","BK4139","BK4548","LU1721429402.USD","SGXZ23171101.USD","LU1061106388.HKD","LU0882574055.USD","SGXZ41872573.SGD","LU1023059063.AUD","ABT","LU1989763690.USD","BK4568","BK4588","SG9999004303.SGD","LU1989763427.SGD","LU1861558580.USD","BK4504","LU2211815571.USD","BK4082","EXAS","IE00BFTCPJ56.SGD","ABT.AU","LU2468319806.SGD","BK4585","LU1914381329.SGD","BK4592","LU1057294990.SGD","LU0868494617.USD","LU0289739699.SGD","LU2112291526.USD","LU2324357040.USD","LU0058720904.USD","LU2237957811.SGD","LU0114720955.EUR","IE00B2B36J28.USD","LU2133065610.SGD","IE0002141913.USD","LU2237957902.USD","IE00BJJMRZ35.SGD","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619086116","title":"Abbott Laboratories' Structural Heart Business Could See Upside From Watchman Trial Results, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2619086116","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619086116?lang=en_us&edition=fundamental","pubTime":"2026-03-13 23:33","pubTimestamp":1773416003,"startTime":"0","endTime":"0","summary":"Abbott Laboratories'  structural heart business could see \"meaningful upside\" from readout of positive results of Boston Scientific's  clinical trial of the Watchman implant at the end of March, UBS said in a note emailed Friday.Positive trial results could spark a broader growth in the structural heart area that could indirectly lift Abbott's MedTech segment through a modest market capture, UBS analysts said. Their scenario analysis suggests that even small market share gains have the potential to raise the MedTech segment's five-year compound annual growth rate to sustainable double-digit growth levels, compared to the consensus of 9.6% over the 2025-2030 period.Although the company's shares have been down 11% year-to-date from 52-week highs partly due to investors' concerns about deceleration in key growth areas within the MedTech segment, the analysts said they believe that the structural heart division remains \"underappreciated.\"UBS reiterated the company's stock rating at buy and","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2133065610.SGD","SG9999002224.SGD","BK4592","LU0353189680.USD","LU0266013472.USD","LU0345769128.USD","LU2357305700.SGD","LU0225283273.USD","LU1983299246.USD","IE0009355771.USD","BSX","LU0432979614.USD","LU0868494617.USD","LU2237957811.SGD","LU0882574055.USD","ABT.AU","LU0058720904.USD","SG9999001176.USD","LU1691799644.USD","LU0048584097.USD","LU1720051017.SGD","IE00BFTCPJ56.SGD","LU1718418525.SGD","LU0823416689.USD","BK4504","IE00BJJMRZ35.SGD","LU1914381329.SGD","LU2491050154.USD","BK4581","LU1804176565.USD","LU2362541513.USD","LU1061106388.HKD","ABT","LU0011850046.USD","LU1023059063.AUD","LU2244417387.USD","LU0234572021.USD","LU2211815571.USD","BSX.AU","LU1989772923.USD","LU1989763427.SGD","LU0122379950.USD","LU1989772840.SGD","LU2324357040.USD","LU2491049909.HKD","BK4588","LU0187121727.USD","LU1721429402.USD","IE00BJT1NW94.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618939739","title":"Is It Time To Revisit Abbott Laboratories (ABT) After Recent Share Price Weakness?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618939739","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618939739?lang=en_us&edition=fundamental","pubTime":"2026-03-10 17:26","pubTimestamp":1773134781,"startTime":"0","endTime":"0","summary":"If you are wondering whether Abbott Laboratories is attractively priced at around US$112.65 today, you are not alone. This article is here to unpack what that price could mean for long term investors.\nThe stock has had mixed returns, with a 1.3% decline over the last 7 days, a 1.6% gain over the last 30 days, and longer term returns of a 9.3% decline year to date, a 16.5% decline over 1 year, 21.7% over 3 years, and 4.5% over 5 years.\nRecent headlines around Abbott have focused on its...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-it-time-to-revisit-abbott-laboratories-abt-after-recent-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-it-time-to-revisit-abbott-laboratories-abt-after-recent-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4504","LU1061106388.HKD","DCF","LU2211815571.USD","SG9999002224.SGD","SGXZ41872573.SGD","LU0122379950.USD","ABT","LU2133065610.SGD","IE00B4R5TH58.HKD","LU1023059063.AUD","SGXZ23171101.USD","LU0170899867.USD","LU0114720955.EUR","LU0882574055.USD","LU2237957811.SGD","BK4566","BK4592","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU1989763690.USD","LU0058720904.USD","BK4581","LU1914381329.SGD","LU0234572021.USD","SG9999002232.USD","BK4588","BK4082","LU2237957902.USD","BK4568","BK4585","IE0009355771.USD","LU2112291526.USD","BK4533","IE00BJT1NW94.SGD","SG9999004303.SGD","IE00BFTCPJ56.SGD","LU2089984988.USD","LU2324357040.USD","LU1989763427.SGD","LU0868494617.USD","LU0289739699.SGD","LU1721429741.USD","LU1691799644.USD","ABT.AU","IE0002141913.USD","LU1057294990.SGD","LU1721429402.USD","LU0266013472.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613732586","title":"A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Moves","url":"https://stock-news.laohu8.com/highlight/detail?id=2613732586","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613732586?lang=en_us&edition=fundamental","pubTime":"2026-02-24 03:27","pubTimestamp":1771874843,"startTime":"0","endTime":"0","summary":"Why Abbott Laboratories (ABT) is Back on Investors’ Radar\nAbbott Laboratories (ABT) is drawing fresh attention after recent share price moves, with the stock roughly flat over the past week but showing a gain over the past month and weaker returns over the past year.\nSee our latest analysis for Abbott Laboratories.\nAt a share price of US$112.21, Abbott’s recent 4.46% 1 month share price return contrasts with its weaker year to date share price performance and a 15.27% 1 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/a-look-at-abbott-laboratories-abt-valuation-after-recent-sha-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/a-look-at-abbott-laboratories-abt-valuation-after-recent-sha-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SGXZ41872573.SGD","IE00B4R5TH58.HKD","BK4504","IE00BJT1NW94.SGD","LU2112291526.USD","LU0122379950.USD","LU0114720955.EUR","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU1691799644.USD","LU2133065610.SGD","IE0009355771.USD","LU1989763427.SGD","IE00BJJMRZ35.SGD","LU1061106388.HKD","LU2089984988.USD","LU0266013472.USD","SG9999002224.SGD","SG9999004303.SGD","LU0058720904.USD","LU0170899867.USD","LU1023059063.AUD","ABT.AU","LU0868494617.USD","BK4581","SG9999002232.USD","LU1914381329.SGD","SGXZ23171101.USD","LU0234572021.USD","BK4566","BK4568","IE00B2B36J28.USD","ABT","IE0002141913.USD","BK4592","LU1721429402.USD","LU2237957811.SGD","BK4585","LU2211815571.USD","LU0882574055.USD","LU1989763690.USD","BK4082","BK4588","LU2237957902.USD","LU1057294990.SGD","BK4533","LU2324357040.USD","LU1721429741.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609597811","title":"Abbott Laboratories Says Late-Breaking Data Supports Safety, Efficacy of Ablation Catheters","url":"https://stock-news.laohu8.com/highlight/detail?id=2609597811","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609597811?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:18","pubTimestamp":1770391097,"startTime":"0","endTime":"0","summary":"Abbott Laboratories  said Friday clinical data from two late-breaking presentations demonstrated the safety and efficacy of its minimally invasive ablation catheters for treating atrial fibrillation.Data from the study showed the Volt pulsed field ablation system achieved an 84.2% freedom from documented rhythm recurrence at 12 months in patients with paroxysmal atrial fibrillation. In patients with persistent atrial fibrillation, nearly 68% remained free from an additional episode following treatment, according to the company.Abbott said the single-arm study also found fewer therapy applications per vein, a repeat ablation rate of less than 6%, and significant improvements in patient-reported quality of life scores.The company also reported new data from a trial evaluating its sensor-enabled TactiFlex duo ablation catheter in more complex atrial fibrillation cases.Six-month data showed an 81% freedom from documented rhythm recurrence in paroxysmal atrial fibrillation patients, along w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0122379950.USD","SG9999004303.SGD","IE00BJT1NW94.SGD","BK4566","LU0058720904.USD","LU1023059063.AUD","LU2237957811.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","IE00B2B36J28.USD","LU0170899867.USD","LU1721429741.USD","LU1989763690.USD","BK4533","LU1691799644.USD","LU1914381329.SGD","LU2468319806.SGD","LU2324357040.USD","LU2089984988.USD","LU2112291526.USD","BK4588","LU1057294990.SGD","BK4581","SGXZ23171101.USD","IE0009355771.USD","LU1061106388.HKD","IE00BJJMRZ35.SGD","ABT","ABT.AU","LU0234572021.USD","SGXZ41872573.SGD","LU0289739699.SGD","LU2237957902.USD","LU2133065610.SGD","LU0882574055.USD","BK4585","BK4592","BK4082","BK4568","BK4504","SG9999002224.SGD","LU1989763427.SGD","LU2211815571.USD","SG9999002232.USD","IE00BFTCPJ56.SGD","LU0868494617.USD","LU1721429402.USD","LU0114720955.EUR","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605000454","title":"Abbott Laboratories' MedTech Business Sustains Momentum Amid Nutrition Weakness, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2605000454","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605000454?lang=en_us&edition=fundamental","pubTime":"2026-01-24 04:15","pubTimestamp":1769199352,"startTime":"0","endTime":"0","summary":"Abbott Laboratories'  fourth-quarter results were weighed down by weakness in its Nutrition business, but the stock's pullback presents an opportunity, supported by resilient earnings and strong MedTech growth, UBS Securities said in a Thursday note.UBS noted that despite Abbott's organic sales growth, excluding COVID, slowing to 3.8% in the fourth quarter, it remains confident in management's 2026 organic growth guidance of 6.5% to 7.5%, citing underappreciated MedTech tailwinds.The brokerage highlighted a rebound in electrophysiology following the US Volt launch, potential upside from an upcoming large left atrial appendage closure trial, and strong demand for Libre continuous glucose monitoring products.While uncertainty remains in Nutrition, which accounts for about 20% of sales, UBS said MedTech strength and accelerating growth into 2026 support a more positive view on the stock.UBS maintained its buy rating with a price target of $158.Shares of Abbott Laboratories were down 1.3% ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABT.AU","LU1057294990.SGD","LU0289739699.SGD","LU2089984988.USD","SGXZ23171101.USD","IE0002141913.USD","LU0122379950.USD","BK4082","LU0868494617.USD","LU2211815571.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0266013472.USD","SG9999002224.SGD","BK4588","LU0234572021.USD","LU2324357040.USD","LU0114720955.EUR","LU2468319806.SGD","IE00BJJMRZ35.SGD","LU1691799644.USD","BK4566","LU0170899867.USD","LU1721429741.USD","BK4533","BK4585","IE00BJT1NW94.SGD","BK4504","LU1989763427.SGD","LU2112291526.USD","LU2237957902.USD","ABT","LU1914381329.SGD","LU0882574055.USD","LU2237957811.SGD","LU1989763690.USD","IE0009355771.USD","BK4592","SG9999004303.SGD","SGXZ41872573.SGD","LU1023059063.AUD","LU1061106388.HKD","LU1721429402.USD","IE00B4R5TH58.HKD","BK4568","BK4581","LU0058720904.USD","SG9999002232.USD","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605340237","title":"Abbott Laboratories Expects H2 Growth Driven by Product Launches, Nutrition Recovery, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2605340237","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605340237?lang=en_us&edition=fundamental","pubTime":"2026-01-24 01:14","pubTimestamp":1769188469,"startTime":"0","endTime":"0","summary":"Abbott Laboratories (ABT) expects growth to accelerate in the second half of 2026, supported by new product launches, recovering Nutrition and Diagnostics businesses and easier year-over-year comparis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0289739699.SGD","LU2237957811.SGD","BK4581","IE00BFTCPJ56.SGD","LU1721429402.USD","IE00B2B36J28.USD","LU2089984988.USD","LU2133065610.SGD","SG9999002224.SGD","BK4082","BK4585","BK4568","ABT.AU","LU0266013472.USD","IE0009355771.USD","LU1057294990.SGD","BK4588","BK4566","BK4592","LU1061106388.HKD","BK4504","LU0868494617.USD","LU0114720955.EUR","LU0170899867.USD","LU1989763690.USD","LU2112291526.USD","LU1989763427.SGD","LU1721429741.USD","LU2468319806.SGD","LU1914381329.SGD","IE00BJT1NW94.SGD","LU1691799644.USD","LU0122379950.USD","SGXZ41872573.SGD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU2237957902.USD","SG9999004303.SGD","SGXZ23171101.USD","BK4533","LU2211815571.USD","LU0058720904.USD","LU0882574055.USD","ABT","LU2324357040.USD","SG9999002232.USD","IE0002141913.USD","LU0234572021.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}]}}